Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
January 5, 2005
Randomized trial of high- and low-source strength (125)I prostate seed implants
Vrinda Narayana, Sara Troyer, Vicki Evans, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 20, 2005
Functional anatomy of the prostate: implications for treatment planning
Patrick W McLaughlin, Sara Troyer, Sally Berri, et al.
Medical Physics
|
March 26, 2005
Use and uncertainties of mutual information for computed tomography/ magnetic resonance (CT/MR) registration post permanent implant of the prostate
Peter L Roberson, P William McLaughlin, Vrinda Narayana, et al.
Physics in Medicine and Biology
|
April 29, 2008
Assessment of skin dose for breast chest wall radiotherapy as a function of bolus material
Shu-Hui Hsu, Peter L Roberson, Yu Chen, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 10, 2013
Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters
Peter L Roberson, Scott J Wilderman, Anca M Avram, et al.
Brachytherapy
|
September 18, 2004
The use of mutual information in registration of CT and MRI datasets post permanent implant
Patrick W McLaughlin, Vrinda Narayana, Marc Kessler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 2019
Prediction of Tumor Control in <sup>90</sup>Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics
Yuni K Dewaraja, Theresa Devasia, Ravi K Kaza, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 22, 2010
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma
Peter L Roberson, Hanan Amro, Scott J Wilderman, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 27, 2005
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region
Buck E Rogers, Peter L Roberson, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 31, 2017
Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma
Peter L Roberson, Lauren B Smith, Meredith A Morgan, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
International Journal of Radiation Oncology, Biology, Physics
|
January 5, 2005
Randomized trial of high- and low-source strength (125)I prostate seed implants
Vrinda Narayana, Sara Troyer, Vicki Evans, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 20, 2005
Functional anatomy of the prostate: implications for treatment planning
Patrick W McLaughlin, Sara Troyer, Sally Berri, et al.
Medical Physics
|
March 26, 2005
Use and uncertainties of mutual information for computed tomography/ magnetic resonance (CT/MR) registration post permanent implant of the prostate
Peter L Roberson, P William McLaughlin, Vrinda Narayana, et al.
Physics in Medicine and Biology
|
April 29, 2008
Assessment of skin dose for breast chest wall radiotherapy as a function of bolus material
Shu-Hui Hsu, Peter L Roberson, Yu Chen, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 10, 2013
Biological-effect modeling of radioimmunotherapy for non-hodgkins lymphoma: determination of model parameters
Peter L Roberson, Scott J Wilderman, Anca M Avram, et al.
Brachytherapy
|
September 18, 2004
The use of mutual information in registration of CT and MRI datasets post permanent implant
Patrick W McLaughlin, Vrinda Narayana, Marc Kessler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 2019
Prediction of Tumor Control in <sup>90</sup>Y Radioembolization by Logit Models with PET/CT-Based Dose Metrics
Yuni K Dewaraja, Theresa Devasia, Ravi K Kaza, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 22, 2010
Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma
Peter L Roberson, Hanan Amro, Scott J Wilderman, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 27, 2005
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region
Buck E Rogers, Peter L Roberson, Sui Shen, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
October 31, 2017
Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma
Peter L Roberson, Lauren B Smith, Meredith A Morgan, et al.
Page
of 3